Literature DB >> 24583794

Estrogen receptor mutations in breast cancer--new focus on an old target.

Corrinne V Segal1, Mitch Dowsett.   

Abstract

Recent studies have provided strong evidence for the emergence of substantial numbers of constitutively active ESR1 mutations in estrogen receptor-positive metastatic breast cancer that are undetected in primary disease. Some of these mutants remain partially sensitive to current anti-estrogen therapies but effective therapeutics targeted at them may require new approaches. ©2014 AACR.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24583794     DOI： 10.1158/1078-0432.CCR-14-0067

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  17 in total

Review 1.  Metastatic breast cancer: The Odyssey of personalization.

Authors:  A Sonnenblick; N Pondé; M Piccart
Journal:  Mol Oncol       Date:  2016-07-11       Impact factor: 6.603

2.  Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells.

Authors:  Carmela Paolillo; Zhaomei Mu; Giovanna Rossi; Matthew J Schiewer; Thomas Nguyen; Laura Austin; Ettore Capoluongo; Karen Knudsen; Massimo Cristofanilli; Paolo Fortina
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

Review 3.  Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health.

Authors:  Balkees Abderrahman; V Craig Jordan
Journal:  Endocrinology       Date:  2018-08-01       Impact factor: 4.736

4.  Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.

Authors:  Nathalie Quenel-Tueux; Marc Debled; Justine Rudewicz; Gaetan MacGrogan; Marina Pulido; Louis Mauriac; Florence Dalenc; Thomas Bachelot; Barbara Lortal; Christelle Breton-Callu; Nicolas Madranges; Christine Tunon de Lara; Marion Fournier; Hervé Bonnefoi; Hayssam Soueidan; Macha Nikolski; Audrey Gros; Catherine Daly; Henry Wood; Pamela Rabbitts; Richard Iggo
Journal:  Br J Cancer       Date:  2015-07-14       Impact factor: 7.640

Review 5.  Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.

Authors:  Cigdem Selli; J Michael Dixon; Andrew H Sims
Journal:  Breast Cancer Res       Date:  2016-12-01       Impact factor: 6.466

6.  Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Authors:  A Harrod; J Fulton; V T M Nguyen; M Periyasamy; L Ramos-Garcia; C-F Lai; G Metodieva; A de Giorgio; R L Williams; D B Santos; P J Gomez; M-L Lin; M V Metodiev; J Stebbing; L Castellano; L Magnani; R C Coombes; L Buluwela; S Ali
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

7.  ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition.

Authors:  Gary K Scott; David Chu; Ravneet Kaur; Julia Malato; Daniel E Rothschild; Katya Frazier; Serenella Eppenberger-Castori; Byron Hann; Ben Ho Park; Christopher C Benz
Journal:  Oncotarget       Date:  2016-10-18

Review 8.  Computational prognostic indicators for breast cancer.

Authors:  Xinan Yang; Xindi Ai; John M Cunningham
Journal:  Cancer Manag Res       Date:  2014-07-12       Impact factor: 3.989

9.  ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors.

Authors:  Lily M Fitzgerald; Eva P Browne; Kevin D Christie; Elizabeth C Punska; Leo O Simmons; Kristin E Williams; Brian T Pentecost; Rahul M Jawale; Christopher N Otis; Kathleen F Arcaro
Journal:  Cancer Cell Int       Date:  2016-02-16       Impact factor: 5.722

Review 10.  Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.

Authors:  Haitao Yang; MariaLynn Jaeger; Averi Walker; Daniel Wei; Katie Leiker; Tao Weitao
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.